Prostate Cancer Clinical Trials in Omaha, Nebraska

14 studies are recruiting for prostate cancer in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026), Omaha, Nebraska

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Nebraska Medical Center Buffet Cancer Center, Omaha, Nebraska

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

   This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with metastatic castration-resistant pro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   XCancer, Omaha, Nebraska

   Locations

   6 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07581184 on ClinicalTrials.gov

4. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

   The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   XCancer Omaha LLC, Omaha, Nebraska

   Locations

   34 in total

   Run by

   Clarity Pharmaceuticals Ltd

   See if you can join NCT06056830 on ClinicalTrials.gov

5. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

6. Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

   This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study i…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   XCancer Omaha, Omaha, Nebraska

   Locations

   14 in total

   Run by

   Monte Rosa Therapeutics, Inc

   See if you can join NCT07745361 on ClinicalTrials.gov

7. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

   This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   19 in total

   Run by

   Pathos AI, Inc.

   See if you can join NCT06785636 on ClinicalTrials.gov

8. Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

   The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e., <1 cm in smallest …

   Stage

   Phase 2

   Ages

   30 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT07237269 on ClinicalTrials.gov

9. Integrated Cancer Repository for Cancer Research

   The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

   Stage

   Not phased

   Ages

   19 to 110

   Site

   Methodist Estabrook Cancer Center, Omaha, Nebraska

   Locations

   42 in total

   Run by

   University of Nebraska

   See if you can join NCT02012699 on ClinicalTrials.gov

10. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

    The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as …

    Stage

    Phase 4

    Ages

    18 to 100

    Site

    Urology Cancer Center PC, Omaha, Nebraska

    Locations

    54 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT05803941 on ClinicalTrials.gov

11. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage

    Phase 2

    Ages

    18 to 100

    Site

    Nebraska Cancer Specialists, Omaha, Nebraska

    Locations

    81 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

12. Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

    To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    XCancer Omaha / Urology Cancer Center, Omaha, Nebraska

    Locations

    21 in total

    Run by

    Blue Earth Therapeutics Ltd

    See if you can join NCT05413850 on ClinicalTrials.gov

13. PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

    Purpose: Prospective, single-site Phase II study testing whether PSMA-PET/MRI-guided, de-escalated salvage radiation reduces acute Grade ≥2 toxicity versus a 44% historical rate, while maintaining cancer control after prostatectomy.Population/Eligibility: Adult men ≥30 years with prior radical pros…

    Stage

    Phase 2

    Ages

    30 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT07234981 on ClinicalTrials.gov

14. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    XCancer Center Omaha/Urology Cancer Center, Omaha, Nebraska

    Locations

    25 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT04729114 on ClinicalTrials.gov